


Ask a doctor about a prescription for CINFAMAR 50 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
cinfamar 50 mg coated tablets
dimenhidrinato
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Follow the administration instructions for the medication contained in this package leaflet or as indicated by your doctor or pharmacist.
Contents of the Package Leaflet
Dimenhidrinato is the active ingredient of this medication and acts against motion sickness caused by means of transportation.
It is indicated for the prevention and treatment of motion sickness symptoms caused by land, sea, or air travel, such as nausea, vomiting, and/or vertigo in adults and children over 12 years of age.
You should consult a doctor if your symptoms worsen or do not improve after 7 days.
Do not take cinfamar:
Warnings and Precautions
Consult your doctor or pharmacist before starting to take cinfamar.
Children
Do not use this medication in children under 2 years of age.
Taking cinfamar with other medications
Inform your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
In particular, if you are taking any of the following medications, it may be necessary to modify the dose of Cinfamar or not take it:
Interference with diagnostic tests
If you are going to undergo any allergy test, including skin tests, it is recommended to suspend treatment 72 hours before starting the test to avoid altering the results.
Taking cinfamar with food, drinks, and alcohol
Alcohol consumption is not recommended during the time you are taking this medication.
It is recommended to take this medication with food or milk.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Taking medications during pregnancy can be hazardous to the embryo or fetus and should be monitored by your doctor.
Breastfeeding women should not take this medication without first consulting their doctor or pharmacist, as this medication passes into breast milk.
Driving and using machines
Do not drive or operate hazardous machinery, as this medication can cause drowsiness or decreased reaction capacity at recommended doses.
Cinfamar contains sodium
This medication contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially "sodium-free".
Follow the administration instructions for the medication contained in this package leaflet or as indicated by your doctor or pharmacist. In case of doubt, ask your doctor or pharmacist.
The recommended doses are:
This medication is taken orally.
It is recommended to take the first dose at least half an hour before starting the trip (preferably 1-2 hours before), and if not taken beforehand, the first dose will be taken when symptoms appear. If motion sickness persists, wait at least 4 or 6 hours between doses.
It is recommended to take the tablets with food, water, or milk to minimize gastric irritation. If symptoms worsen or persist for more than 7 days, consult your doctor.
If you take more cinfamar than you should
If you have taken Cinfamar more than you should, consult your doctor or pharmacist immediately.
Symptoms of overdose include mainly: dilated pupils, red face, excitement, hallucinations, confusion, stomach and intestine irritation with nausea, vomiting, and diarrhea, movement disorders, convulsions, deep loss of consciousness (coma), sudden decrease in heart and respiratory functions (cardiorespiratory collapse), and death. Symptoms may take more than 2 hours to appear after overdose.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Side effects are usually mild and transient, especially at the beginning of treatment.
During the use of dimenhidrinato, the following adverse reactions have been observed, whose frequency could not be established with precision:
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medication Surveillance System for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
This medication does not require special storage conditions.
Do not use this medication after the expiration date shown on the box and label after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Composition of cinfamar
Appearance of the product and package contents
White, cylindrical, biconvex, and scored coated tablets.
Available in packages of 4 or 10 coated tablets.
Marketing authorization holder and manufacturer
Laboratorios Cinfa, S.A.
Carretera Olaz-Chipi, 10. Polígono Industrial Areta
31620 Huarte (Navarra) - Spain
Date of the last revision of this package leaflet:December 2020
Detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.es/
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for CINFAMAR 50 mg FILM-COATED TABLETS – subject to medical assessment and local rules.